The previously leading case, Canada v. Aqua-Gem Investments, held that if the issue under appeal was “vital,” it was reviewed de novo as if the underlying decision had never been made. Determining vitality required case-by-case dissection of the matter at issue and was often unpredictable. Harmonizing the standard of review recognizes that Prothonotaries are presumed to be fit to decide matters assigned to them and will lead to greater simplicity and certainty.
The standard of review issue arose in the context of a discovery appeal in ongoing patent litigation between Hospira/Celltrion and Janssen/The Kennedy Trust for Rheumatology Research, involving the biologic drug Remicade. The appellants, Hospira/Celltrion, sought an additional half-day of inventor discovery to be conducted in-person as opposed to teleconference as ordered by the Prothonotary at first instance. The Court dismissed the appeal. The bulk of the Court’s reasons, however, concerned the standard of review.